# Advances in HPV Vaccination in People Living with HIV: A Review

## TL;DR

This paper reviews how HPV vaccination can help people with HIV, who face higher cancer risks from HPV, and highlights the need for better vaccine access and awareness.

## Contribution

The paper provides a comprehensive review of HPV vaccination effectiveness and barriers in people living with HIV, emphasizing the need for optimized strategies.

## Key findings

- HPV vaccines are safe and induce strong antibody responses in people living with HIV.
- Vaccination coverage remains low among PLWH, especially in low- and middle-income countries.
- More research is needed to confirm clinical benefits and optimize vaccination schedules for PLWH.

## Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is a leading cause of cervical, anal, penile, and oropharyngeal cancers. This review summarizes the epidemiology of HPV and the immunogenicity, clinical efficacy, and current HPV vaccination recommendations among people living with HIV (PLWH). PLWH experience a disproportionate burden of HPV-related infection and HPV-related malignancies. Although HPV vaccines have been shown to be highly effective, vaccination coverage among PLWH remains suboptimal, particularly in low- and middle-income countries. Barriers to vaccination include extended dosing schedules, limited awareness of the vaccine, and misinformation. Evidence indicates HPV vaccines are safe and induce a robust antibody response in PLWH, especially among individuals with higher CD4+ cell counts and viral suppression on antiretroviral therapy. However, evidence for reduction in clinical HPV-related disease in this population remains limited. Ongoing research is aimed at optimizing the HPV vaccination schedule for PLWH and expanding vaccination in older, high-risk subgroups. Integrating HPV vaccination into HIV care is essential to reduce HPV-related morbidity and mortality in PLWH.